Congrats! Inxmed received $15 million in Series B+ financing!Accelerating focusing on breakthroughs in solid tumor drug resistance and tumor microenvironment fibrosis!
Inxmed Biotechnology (Nanjing) Co , Ltd , a global innovative drug research and development company focusing on breakthroughs in solid tumor drug resistance,announced that it has completed B+ financing round!